Orum Therapeutics, Inc. 475830

KRX · South Korea · Health Technology

KRW 21,150.00-2,200.00 (-9.42%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Orum Therapeutics, Inc. 475830

KRX · South Korea · Health Technology

KRW 21,150.00-2,200.00 (-9.42%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-73.40% · 6MFull-screen chart

Open KRW 23,200.00High KRW 23,550.00Low KRW 20,950.00Close KRW 21,150.00Volume 516.00K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 23,350.00
Day range: KRW 20,950.00 – KRW 23,550.00
52-week range: KRW 20,850.00 – KRW 146,600.00
Volume: 516.00K
Market cap: KRW 481.83B
P/E (TTM): 24.1
Avg. volume (1Y): 304.16K

Performance

1 week

-12.78%

1 month

-62.43%

3 months

-58.37%

6 months

-72.21%

Year to date

-81.41%

1 year

-37.52%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: South Korea
Exchange: KRX
Shares outstanding: 21.75M
Employees: 21
ISIN: KR7475830006
Beta: 0.58

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceAug 23, 2026

Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate

Company to host a conference call to discuss the ORM-1153 IND clearance and provide a high-level overview of the Phase 1 clinical studyBOSTON and DAEJEON, South Korea, Aug. 22, 2026 (GLOBE NEWSWIRE) -- Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ORM-1153, a CD12

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.